Pinealon
A synthetic tripeptide from Russian bioregulator research; its small regional literature lacks independent replication, and it holds no approval anywhere.
What it is
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the same Russian 'peptide bioregulator' school that produced Epithalon, marketed for brain aging and cognitive protection.
Its literature is small, regional and largely from the originating research lineage — cell and animal studies plus limited Russian clinical reports, without independent replication or any Western regulatory review. It circulates as capsules and vials through supplement-adjacent channels.
What researchers have actually studied it for
Neuronal aging and cognitive protection in the Russian bioregulator literature — small, regional, and without independent replication.
How it works
The bioregulator school proposes that short peptides like Pinealon act epigenetically — entering cells and modulating gene expression relevant to neuronal maintenance. Supporting data comes from the originating laboratories' cell and animal work; independent mechanistic confirmation is absent.
Where it came from
Part of the St. Petersburg bioregulator program's catalog of organ-targeted short peptides developed from the 1980s onward, Pinealon is positioned as the 'brain peptide' sibling of Epithalon. The program's sweeping longevity claims have never been independently replicated.
What the research record actually contains
- Cell and rodent studies from the originating research lineage.
- Russian-language clinical reports outside modern trial standards.
- No independent replication; no Western trials; no regulatory review anywhere.
What's known about risks
The originating literature reports benign tolerability; no independent safety characterization exists.
Where it stands legally
No approval anywhere; supplement-adjacent and research-chemical channels only.
Worth asking a licensed provider
- 1.Is there any independently verified evidence here at all?
- 2.For cognitive concerns, what established work-up and interventions come first?
- 3.How would we even measure benefit from an unvalidated compound?